Back
Top 1%
22.4%
Top 3%
9.1%
Top 71%
6.5%
Top 1%
6.0%
Top 3%
6.0%
Top 1%
4.2%
Top 0.6%
3.9%
Top 2%
3.9%
Top 66%
3.9%
Top 12%
3.9%
Top 2%
2.8%
Top 6%
2.0%
Top 13%
1.5%
Top 0.9%
1.2%
Top 8%
1.2%
Top 5%
1.0%
Top 4%
1.0%
Top 7%
0.7%
Top 7%
0.7%
Top 67%
0.7%
Top 5%
0.7%
Top 17%
0.7%
Top 10%
0.7%
TNF blockade with certolizumab improves the efficacy of anti-PD-1 and anti-CTLA-4 combination therapy for melanoma
2026-02-14
oncology
Title + abstract only
View on medRxiv
Show abstract
The phase 1b TICIMEL clinical trial evaluated the safety, tolerability, and anti-tumor activity of combining the immune checkpoint inhibitors (ICI), ipilimumab and nivolumab, with tumor necrosis factor (TNF) blockers, certolizumab or infliximab, to treat advanced melanoma patients. A higher proportion of responses was observed in patients receiving ICI and certolizumab, while patients treated with ICI and infliximab demonstrated superior tolerability. Moreover, CITE-Seq analyses of circulating C...
Predicted journal destinations
1
Nature Communications
483 training papers
2
Cancers
57 training papers
3
PLOS ONE
1737 training papers
4
Clinical Cancer Research
22 training papers
5
Frontiers in Oncology
34 training papers
6
British Journal of Cancer
22 training papers
7
BMC Cancer
21 training papers
8
Proceedings of the National Academy of Sciences
100 training papers
9
Scientific Reports
701 training papers
10
eLife
262 training papers
11
Cancer Medicine
17 training papers
12
Frontiers in Immunology
140 training papers
13
JAMA Network Open
125 training papers
14
Cell Reports
25 training papers
15
iScience
74 training papers
16
Cell Reports Medicine
49 training papers
17
Journal of Clinical Investigation
50 training papers
18
International Journal of Molecular Sciences
39 training papers
19
Communications Medicine
63 training papers
20
BMJ Open
553 training papers
21
Communications Biology
36 training papers
22
Nature Medicine
88 training papers
23
Nature
58 training papers